STERO Biotechs Ltd.
STERO BIOTECH LTD., A CLINICAL STAGE COMPANY:
STERO Ltd., founded in 2017 and headquartered in Israel, is a clinical-stage company committed to the research and development of novel and improved Cannabidiol (CBD) based treatment solutions that will potentially benefit millions of patients by reducing the side effects and the need of steroid therapy.
STERO’s patent was granted on August 2018 and the first clinical trial will commence on Q4 2018 on the first indications with more indications planned in the pipeline.
A HUGE MARKET OPPORTUNITY:
STERO addresses a huge market opportunity. Steroids are the first line of treatment of many conditions, such as inflammatory and autoimmune diseases, including AutoImmune Hepatitis, rheumatoid arthritis, lupus, IBD, psoriasis and more.
REDUCING THE NEED FOR STEROIDS:
There is an urgent clinical unmet need to lower the dosage and the time period of Steroids administration.
STERO committed to the research and development of novel and improved Cannabidiol (CBD) based treatment solution.
STERO aims to solve this unmet need by offering CBD based treatment that will reduce Steroids’ side effects.
STERO’s Solution will potentially benefit millions of patients suffering from the negative Implications of Steroids treatment.
The company plans to validate its concept in various autoimmune diseases.
The company’s first product ST-101 is targeted for autoimmune hepatitis, an orphan autoimmune liver disease which requires long-term steroid treatment as immunosuppressive medication. A phase IIa clinical trial is planned to commence on Q3 2018.
Other indications in our pipeline are planned to be researched in 2019.